PET Imaging as a Predictor of Immune Checkpoint Inhibitor Efficacy for Lung Neuroendocrine Tumors

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K07627
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 52040:Radiological sciences-related
• Research Institution: Saitama Medical University
• Principal Investigator: Imai Hisao 埼玉医科大学, 医学部, 准教授 (10646483)
• Co-Investigator(Kenkyū-buntansha): 解良 恭一 埼玉医科大学, 医学部, 教授 (40400783)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: 免疫チェックポイント阻害薬 / 肺神経内分泌腫瘍 / PETイメージング / 進展型小細胞肺癌 / 薬物療法 / 効果予測因子

Outline of Final Research Achievements

Patients with extensive disease small cell lung cancer (ED-SCLC) who underwent 18F-FDG-PET prior to initiation of first-line PD-L1 antibody-based chemotherapy were included in the study. 18F-FDG uptake maximum standard uptake value (SUVmax), metabolic tumor volume (MTV ) and total lesion glycolysis (TLG) were evaluated. Sex, Brinkman index, and MTV were independent prognostic predictors of PFS, while gender, SUVmax, MTV, and TLG were significant predictors of OS. MTV or TLG metabolic tumor activity is a promising prognostic indicator for chemo-immunotherapy in patients with ED-SCLC.

Free Research Field

臨床腫瘍学

Academic Significance and Societal Importance of the Research Achievements

初回治療としてPD-L1抗体を併用したプラチナ製剤ベースの化学療法開始前に18F-FDG-PETで評価したmetabolic tumor volume (MTV)またはtotal lesion glycolysis (TLG) 代謝腫瘍活性は、進展型小細胞肺癌患者における化学-免疫療法の治療成績の予測に有望である可能性がある。